Novo Nordisk has taken the next step in selling its drugs directly to patients by pointing them to telehealth providers that ...

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

One of the more interesting moves that came this quarter was from the Duquesne Family Office, led by billionaire investor ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Hims & Hers Health (NYSE:HIMS) is positioning itself to capitalize on Novo Nordisk's (NYSE:NVO) mounting struggles in the ...